We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 7 september 2017

The Lancet: [Comment] GeDDiS: insight into frontline therapy in soft tissue sarcoma

[Comment] GeDDiS: insight into frontline therapy in soft tissue sarcoma
Gemcitabine has known activity in sarcoma; although its exact role, indication, or best combination is still debated. The combination of gemcitabine and docetaxel gained favour in the USA after efficacy was noted in uterine leiomyosarcoma1,2 and later in sarcoma, generally with superiority over gemcitabine alone.3 However, this combination is used to a lesser extent in Europe, partly due to more equivocal data in leiomyosarcoma,4 noted efficacy of other gemcitabine-based regimens,5 and potential issues of access as described in the GeDDiS6 trial in The Lancet Oncology.
Read more

[News] Thalidomide reduces chemotherapy-induced vomiting
Delayed nausea and vomiting induced by highly emetogenic chemotherapy could be significantly improved through a combination of thalidomide, palonosetron, and dexamethasone, new research suggests.
Read more

[News] Use of cancer-related emergency departments
Of the estimated 696 million visits made by adults to US emergency departments between 2006 and 2012, 29·5 million (4·2%) were for cancer-related complications, according to the results of a new study.
Read more

[News] Eribulin: an effective therapeutic option in liposarcoma
A subgroup analysis of a phase 3 trial suggests that eribulin significantly improves survival outcomes compared with dacarbazine in patients with pretreated liposarcoma—a soft-tissue sarcoma subtype with very few efficacious therapies.
Read more

[News] E-cigarette use in young people in the UK
Regular use of electronic cigarettes (e-cigarettes) by 11–16 year olds is low (1–3%), and most experimental use does not lead to regular use or increase smoking prevalence, according to an analysis of findings from five surveys done in the UK between 2015 and 2017.
Read more